side effects from compounded semaglutide vs. Wegovy Patients report alarming side effects

In the ACHIEVE-3 head-to-head trial published in The Lancet in February 2026, orforglipron 36 mg delivered 73.6% greater relative weight loss than oral semaglutide (14 mg) in people with type 2 diabetes 9.2% body weight loss vs

(figure 6)

High serum folate levels They can also increase the likelihood of anemia

GLP-1 medications explained Glucagon-like peptide-1 receptor agonists (or GLP-1 RAs) are a class of drugs used to treat type 2 diabetes and obesity

JCI Insight 8:e167395

The test identifies genetic variants in GLP1R and GIPR receptors that influence your likelihood of experiencing intense nausea or rapid adaptation